Advanced Search
ZHANG Hao, XI Ya-ming, XU Jian-wang, LI Ming, LI Pei, DENG Wei. XRCC1 Polymorphisms and Lymphoma Risk:A Meta-analysis of Case-Control Studies[J]. Cancer Research on Prevention and Treatment, 2011, 38(10): 1181-1186. DOI: 10.3971/j.issn.1000-8578.2011.10.023
Citation: ZHANG Hao, XI Ya-ming, XU Jian-wang, LI Ming, LI Pei, DENG Wei. XRCC1 Polymorphisms and Lymphoma Risk:A Meta-analysis of Case-Control Studies[J]. Cancer Research on Prevention and Treatment, 2011, 38(10): 1181-1186. DOI: 10.3971/j.issn.1000-8578.2011.10.023

XRCC1 Polymorphisms and Lymphoma Risk:A Meta-analysis of Case-Control Studies

More Information
  • Received Date: August 15, 2010
  • Revised Date: April 20, 2011
  • ObjectiveTo evaluate the association between X-ray repair cross-complementing group1(XRCC1) gene polymorphisms and lymphoma risk by means of Meta-analysis. Methods We searched PubMed,EMbase,Chinese National Knowledge Infrastructure,China Journal Full Text Database,Chinese Biomedical Literature Database up to Feb 2010,the references of eligible studies were searched by hand.Case-Control studies involving X-ray repair cross-complementing group1(XRCC1) genetic polymorphism and lymphoma risk were included.Data were extracted independently by two reviewers according to designed extraction.The Cochrane Collaboration's RevMan 5.0 software was applied for statistical analyses. Results A total of 11 studies involving 4 569 patients and 5 746 controls were included.The results of Meta-analysis showed no statistical difference in the frequencies of variant genotypes and wild homozygote of XRCC1 between the Non-Hodgkin's lymphoma patients and controls,but Gln/Gln+Arg/Gln gentype of codon 399 may increase the risk of Hodgkin's lymphoma(OR=1.31,95%CI [1.02,1.69]). Conclusion The polymorphism at codon 399,194 and 280 of XRCC1 are not associated with Non-Hodgkin's lymphoma risk but Gln/Gln+Arg/Gln genotype of codon 399 may increase the risk of Hodgkin,s lymphoma.
  • Related Articles

    [1]HE Yang, YANG Runfeng, ZHOU Yingying, XU Qian, YAN Hao, JIANG Lei, JIANG Xiaohui, HUANG Yi. Effect of Aprepitant on Chemotherapy-induced Adverse Reactions in Gynecological Malignancy Patients[J]. Cancer Research on Prevention and Treatment, 2018, 45(11): 913-916. DOI: 10.3971/j.issn.1000-8578.2018.18.0265
    [2]LI Daojun, XU Xinhua, ZHANG Jianyu, LI Cong. Clinical Observation of Olanzapine in Treatment of Nausea and Vomiting Caused by Opioid Analgesics[J]. Cancer Research on Prevention and Treatment, 2018, 45(5): 326-328. DOI: 10.3971/j.issn.1000-8578.2018.17.1275
    [3]DONG Shuang, WANG Jun, HU Sheng, LIAO Guoxiang, RAN Fengming. Aprepitant versus Olanzapine for Prevention of Nausea and Vomiting Induced by Multi-day Chemotherapy in Female Lung Cancer or Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2017, 44(5): 356-359. DOI: 10.3971/j.issn.1000-8578.2017.05.009
    [4]LI Quanfu, Jin gaowa, WANG Wenjuan, JIANG Caihong, DENG Shuqin, LI Hui, CHEN Feng, BAI Xiaojun, CHEN Gang, HU Yuliang, ZHAO Jun, Dalenggaowa, Wuyungaowa. Clinical Observation of Neurokinin-1 Antagonist Preventing Multiple-day Chemotherapy-induced Nausea and Vomiting[J]. Cancer Research on Prevention and Treatment, 2017, 44(4): 290-294. DOI: 10.3971/j.issn.1000-8578.2017.04.011
    [5]LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
    [6]DONG Shuang, YU Shiying. A Study of Chemotherapy-induced Nausea and Vomiting Involving Different Dosage Regimens of Cisplatin[J]. Cancer Research on Prevention and Treatment, 2013, 40(09): 890-893. DOI: 10.3971/j.issn.1000-8578.2013.09.016
    [7]Xu Lu, Li Chunlai, Li Ling. A Constructive Experimental Study on Prevention of Chemotherapy-induced Nausea and Vomiting by Ginger-partitioned Moxibustion on Acupoint of Zusanli[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 710-712. DOI: 10.3971/j.issn.1000-8578.2012.06.024
    [8]XU Shu, LI Hong, SONG Yu-hong, LI Bin, CAI Hong-bing. Clinical Comparative of Tropisetron Hydrochloride with or without Traditional Chinese Medicine Compound in Prevention of Chemotherapy-induced Nausea and Emesis[J]. Cancer Research on Prevention and Treatment, 2009, 36(09): 787-790. DOI: 10.3971/j.issn.1000-8578.2009.09.021
    [9]MA Lei, MA Hai-long, ZHAO Xu-lin, et al. A Clinical Observation of Tropisetron in Combination with Dexame thasone and Methclopramide in the prevention of High Dose Cisplatin- induced Delayed Nausea and Emesis[J]. Cancer Research on Prevention and Treatment, 2001, 28(06): 469-470. DOI: 10.3971/j.issn.1000-8578.474
    [10]Chen Zhendong, . Medroxyprogesterone Acetate with Antiemetics: Efficacy in ControllingAnorexia, Nausea and Vomiting Induced by Chemotherapy[J]. Cancer Research on Prevention and Treatment, 1996, 23(2): 102-103.

Catalog

    Article views (2271) PDF downloads (402) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return